Vinsamlegast notið þetta auðkenni þegar þið vitnið til verksins eða tengið í það: http://hdl.handle.net/1946/15425
Introduction: Psoriasis is a papulosquamous skin disease, today regarded as a common T cell mediated inflammatory disorder. The disease is characterized by inflammatory skin lesions on various sites of the body. Since cardiovascular diseases have been connected to the inflammatory diseases, specifically atherosclerosis, there is a possibility that psoriasis and cardiovascular diseases are linked through a partly common inflammatory process. This study aims to investigate this relationship and the effect of psoriasis treatments, ultraviolet B (UVB) phototherapy and systemic therapy by a TNFα inhibitor, on the cardiovascular risk factors.
Materials and Methods: Two methods were used for the execution of this study. The Multiplex assay technology was used to measure cardiovascular biomarkers in serum and immunohistochemical staining was used to determine the expression of the Nod-like receptor NLRP-1, which may play a role in the inflammatory process of both psoriasis and atherosclerosis.
Results: When comparing psoriasis patients and healthy controls, five biomarkers were notably increased in the serum of patients. When matching for BMI for the same comparison, only tPAI-1 was significantly up-regulated. Comparison of patients before and after 12 weeks of UVB therapy revealed no significant change in the cardiovascular biomarkers. Comparing patients before and after treatment with a TNFα inhibitor showed a significant decrease in all biomarkers. Immunohistochemical staining of NLRP-1 demonstrated equal staining in patients and controls.
Discussion: The results suggest an increased level of CVD biomarkers in psoriasis patients compared to healthy controls. They also point towards a negligible effect of UVB treatment on the expression levels of the biomarkers. In contrast, a therapeutic effect of TNF-α inhibitor on biomarker concentration is demonstrated. In conclusion, our data suggest that patients with high risk of cardiovascular disease may benefit from the use of systemic treatment.
|Ástríður Pétursdóttir.pdf||3.69 MB||Lokaður til...01.06.2018||Heildartexti|